700125P
Avanti
DMHCA
Avanti Research™ - A Croda Brand 700125P, powder
Synonym(s):
N,N-dimethyl-3β-hydroxycholenamide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 5 mg (700125P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 700125P
shipped in
dry ice
storage temp.
−20°C
General description
N,N-dimethyl-3β-hydroxy-cholenamide (DMHCA) is a potent steroidal liver X receptor (LXR) ligand in vitro and in vivo. It is used to treat atherosclerosis.
N,N-dimethyl-3β-hydroxycholenamide (DHMCA) is a synthetic ligand for liver X receptor (LXR).
Application
DMHCA has been used as LXR activator to treat retinal endothelial cells in order to activate the sirtuin 1- liver X receptors (SIRT1-LXR) pathway.
It may be used as 3β-hydroxysterol-Δ24-reductase (DHCR24) inhibitor.
Biochem/physiol Actions
N,N-dimethyl-3β-hydroxycholenamide (DHMCA) halts cholesterol biosynthesis by inhibiting 3β-hydroxysterol-Δ24-reductase (DHCR24) enzyme. It may serve as a therapeutic agent for treating atherosclerosis, age-related macular degeneration and diabetic retinopathy.
DMHCA (N,N-dimethyl-3β-hydroxycholenamide) is a synthetic oxysterol and is an agonist for liver X receptors (LXR). It promotes cholesterol transport, expression of adenosine triphosphate (ATP) binding cassette transporters. DMHCA suppresses the proinflammatory cytokines stimulation, induced by oxysterol.
Packaging
5 mL Amber Glass Screw Cap Vial (700125P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class
11 - Combustible Solids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor.
Journal of Lipid Research, 45(10), 1929-1942 (2004)
The mechanism of diabetic retinopathy pathogenesis unifying key lipid regulators, sirtuin 1 and liver X receptor
EBioMedicine, 22, 181-190 (2017)
Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein
Gynecologic Oncology, 116(1), 109-116 (2010)
Synthetic LXR agonist attenuates plaque formation in apoE-/-mice without inducing liver steatosis and hypertriglyceridemia
Journal of Lipid Research, 50(2), 312-326 (2009)
Frontiers in pharmacology, 9, 827-827 (2018-08-10)
N,N-dimethyl-3β-hydroxycholenamide (DMHCA) is an experimental pharmaceutical and a steroidal liver X receptor (LXR) agonist, which does not induce undesired hepatic lipogenesis. Herein, DMHCA was evaluated for its retinal effects on normal C57BL/6J and Cyp27a1-/-Cyp46a1-/- mice; the latter having higher retinal
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service